Quantbot Technologies LP Invests $617,000 in HealthEquity, Inc. $HQY

Quantbot Technologies LP acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 6,827 shares of the company’s stock, valued at approximately $617,000.

Several other hedge funds have also added to or reduced their stakes in HQY. Fifth Third Wealth Advisors LLC grew its stake in HealthEquity by 4.2% in the first quarter. Fifth Third Wealth Advisors LLC now owns 2,872 shares of the company’s stock valued at $240,000 after acquiring an additional 116 shares during the period. Truist Financial Corp raised its position in shares of HealthEquity by 4.9% during the fourth quarter. Truist Financial Corp now owns 2,537 shares of the company’s stock worth $232,000 after purchasing an additional 119 shares during the period. Fiduciary Trust Co raised its position in shares of HealthEquity by 3.4% during the third quarter. Fiduciary Trust Co now owns 3,669 shares of the company’s stock worth $348,000 after purchasing an additional 120 shares during the period. Larson Financial Group LLC lifted its holdings in shares of HealthEquity by 24.4% during the 3rd quarter. Larson Financial Group LLC now owns 628 shares of the company’s stock valued at $60,000 after purchasing an additional 123 shares in the last quarter. Finally, Merit Financial Group LLC grew its position in shares of HealthEquity by 8.9% in the 3rd quarter. Merit Financial Group LLC now owns 2,112 shares of the company’s stock valued at $200,000 after purchasing an additional 172 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on HQY shares. KeyCorp restated an “overweight” rating on shares of HealthEquity in a report on Tuesday, May 26th. Barrington Research reissued an “outperform” rating and set a $110.00 price objective on shares of HealthEquity in a research report on Friday, May 22nd. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a research report on Monday, June 1st. Citizens Jmp upped their target price on shares of HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research note on Monday, June 1st. Finally, Citigroup reiterated a “market outperform” rating on shares of HealthEquity in a report on Monday, June 1st. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.93.

Insider Activity

In other news, EVP Michael Henry Fiore sold 2,354 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $95.00, for a total transaction of $223,630.00. Following the completion of the transaction, the executive vice president directly owned 52,244 shares in the company, valued at $4,963,180. This represents a 4.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the transaction, the director owned 62,395 shares of the company’s stock, valued at $6,527,140.95. The trade was a 10.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,456 shares of company stock worth $1,256,664 over the last three months. Insiders own 1.60% of the company’s stock.

Key Headlines Impacting HealthEquity

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted EPS of $1.24 versus the $1.19 consensus and revenue of $350.7 million versus $349.2 million. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved: net income rose 10% to $65.6 million, net margin expanded to 19% from 18%, and adjusted EBITDA increased 11% to $167 million, with the EBITDA margin rising to 48% from 46%. HealthEquity Reports Second Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. HSA assets reached a record $37.9 billion, supporting HealthEquity’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Neutral Sentiment: Revenue guidance was approximately $1.4 billion, broadly in line with analysts’ expectations, meaning the guidance increase was concentrated primarily in earnings rather than sales.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares worth approximately $798,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but it may still add short-term selling pressure. Adrian T. Dillon Insider Transaction
• Negative Sentiment: At roughly 35 times earnings, HQY remains priced for substantial growth. Investors may be using the strong report as an opportunity to lock in gains, particularly after the shares traded near their 52-week high.

HealthEquity Price Performance

Shares of HQY opened at $93.39 on Friday. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $107.62. The stock has a market capitalization of $7.81 billion, a P/E ratio of 34.98, a P/E/G ratio of 1.76 and a beta of 0.21. The company has a 50 day moving average of $97.93 and a 200-day moving average of $87.81.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.05. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The business had revenue of $350.73 million for the quarter, compared to analyst estimates of $349.22 million. The business’s quarterly revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, equities research analysts forecast that HealthEquity, Inc. will post 3.92 EPS for the current fiscal year.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.